Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NSE - Delayed Quote INR

Bafna Pharmaceuticals Limited (BAFNAPH.NS)

80.40
+3.48
+(4.52%)
At close: April 25 at 3:13:46 PM GMT+5:30
Loading Chart for BAFNAPH.NS
  • Previous Close 76.92
  • Open 80.69
  • Bid --
  • Ask --
  • Day's Range 75.00 - 80.70
  • 52 Week Range 69.00 - 113.00
  • Volume 17,982
  • Avg. Volume 2,431
  • Market Cap (intraday) 1.902B
  • Beta (5Y Monthly) 0.47
  • PE Ratio (TTM) 44.18
  • EPS (TTM) 1.82
  • Earnings Date May 27, 2025 - May 31, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Sep 19, 2013
  • 1y Target Est --

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, and internationally. The company was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited operates as a subsidiary of SRJR Lifesciences LLP.

www.bafnapharma.com

363

Full Time Employees

March 31

Fiscal Year Ends

Recent News: BAFNAPH.NS

View More

Performance Overview: BAFNAPH.NS

Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

BAFNAPH.NS
1.90%
S&P BSE SENSEX (^BSESN)
1.37%

1-Year Return

BAFNAPH.NS
7.43%
S&P BSE SENSEX (^BSESN)
6.56%

3-Year Return

BAFNAPH.NS
37.46%
S&P BSE SENSEX (^BSESN)
40.00%

5-Year Return

BAFNAPH.NS
295.09%
S&P BSE SENSEX (^BSESN)
152.86%

Compare To: BAFNAPH.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BAFNAPH.NS

View More

Valuation Measures

Annual
As of 4/25/2025
  • Market Cap

    1.89B

  • Enterprise Value

    2.06B

  • Trailing P/E

    44.18

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.28

  • Price/Book (mrq)

    2.30

  • Enterprise Value/Revenue

    1.39

  • Enterprise Value/EBITDA

    16.52

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.90%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.48B

  • Net Income Avi to Common (ttm)

    42.97M

  • Diluted EPS (ttm)

    1.82

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.15M

  • Total Debt/Equity (mrq)

    22.75%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: BAFNAPH.NS

View More

Company Insights: BAFNAPH.NS

Research Reports: BAFNAPH.NS

View More

People Also Watch